Jennifer S. Michaelson
Biogen Idec
Cambridge
USA
Name/email consistency: high
- The anti-Fn14 antibody BIIB036 inhibits tumor growth in xenografts and patient derived primary tumor models and enhances efficacy of chemotherapeutic agents in multiple xenograft models. Michaelson, J.S., Kelly, R., Yang, L., Zhang, X., Wortham, K., Joseph, I.B. Cancer Biol. Ther. (2012)
- Anti-tumor activity of stability-engineered IgG-like bispecific antibodies targeting TRAIL-R2 and LTbetaR. Michaelson, J.S., Demarest, S.J., Miller, B., Amatucci, A., Snyder, W.B., Wu, X., Huang, F., Phan, S., Gao, S., Doern, A., Farrington, G.K., Lugovskoy, A., Joseph, I., Bailly, V., Wang, X., Garber, E., Browning, J., Glaser, S.M. MAbs (2009)
- Therapeutic targeting of TWEAK/Fnl4 in cancer: exploiting the intrinsic tumor cell killing capacity of the pathway. Michaelson, J.S., Burkly, L.C. Results. Probl. Cell. Differ (2009)
- Tweak induces mammary epithelial branching morphogenesis. Michaelson, J.S., Cho, S., Browning, B., Zheng, T.S., Lincecum, J.M., Wang, M.Z., Hsu, Y.M., Burkly, L.C. Oncogene (2005)